Home    Back

Transdihydrolisuride    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease0
86Pulmonary arterial hypertension4

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 2,123 trial found

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-003975-38-AT
(EUCTR)		03/10/201028/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension		Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride		Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes		99Phase 2Czech Republic;Germany;Netherlands;Austria
2EUCTR2007-003975-38-CZ
(EUCTR)		19/05/200913/02/2009Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension		Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride		Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes		84Phase 2Germany;Czech Republic;Netherlands;Austria
3EUCTR2007-003975-38-NL
(EUCTR)		18/02/200817/10/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension		Product Name: Terguride 0,5mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride		Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes		84Phase 2Czech Republic;Germany;Netherlands;Austria
4EUCTR2007-003975-38-DE
(EUCTR)		22/11/200728/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension		Product Name: Terguride 0,5mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride		Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes		99Phase 2Czech Republic;Austria;Netherlands;Germany